A 12-week DBPC Dose-finding Study with Sublingual Monomeric Allergoid Tablets in House Dust Mite-allergic Patients

Overview

Journal Allergy

Specialty Allergy & Immunology

Date 2016 Apr 13

PMID 27068870

Citations 9

Authors

C Huser

P Dieterich

J Singh

K Shah-Hosseini

S Allekotte

W Lehmacher

E Compalati

R Mosges

Affiliations

Soon will be listed here.

Abstract

Background: In sublingual immunotherapy, optimal doses are a key factor for therapeutic outcomes. The aim of this study with tablets containing carbamylated monomeric house dust mite allergoids was to determine the most effective and safe dose.

Methods: In this double-blind, placebo-controlled dose-finding study, 131 patients with house dust mite-induced allergic rhinoconjunctivitis were randomized to 12-week treatments with 300 UA/day, 1000 UA/day, 2000 UA/day, 3000 UA/day or placebo. Conjunctival provocation tests (CPT) were performed before, during and after treatment. The change in mean allergic severity (primary endpoint), calculated from the severity of the CPT reaction, and the proportion of patients with an improved CPT threshold (secondary endpoint) determined the treatment effect.

Results: The mean allergic severity decreased in all groups, including the placebo group. It was lower in all active treatment groups (300 UA/day: 0.14, 1000 UA/day: 0.15, 2000 UA/day: 0.10, 3000 UA/day: 0.15) than in the placebo group (0.30). However, this difference was not statistically significant (P < 0.1). The percentage of patients with an improved CPT threshold was higher in the active treatment groups (300 UA/day: 73.9%; 1000 UA/day: 76.0%; 2000 UA/day: 88.5%; 3000 UA/day: 76.0%) than in the placebo group (64.3%). The difference between placebo and 2000 UA/day was statistically significant (P = 0.04). In 13 (10%) exposed patients, a total of 20 treatment-related adverse events of mild severity were observed.

Conclusions: The 12-week daily treatment using 2000 UA/day monomeric allergoid sublingual tablets is well tolerated and reduces the CPT reaction in house dust mite-allergic patients.

Citing Articles

The evidence for commercial house dust mite immunotherapy products: A pragmatic systematic review with narrative synthesis.

West T, Katelaris C J Allergy Clin Immunol Glob. 2024; 3(3):100255.

PMID: 39092213 PMC: 11292502. DOI: 10.1016/j.jacig.2024.100255.

Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of....

Pfaar O, Ankermann T, Augustin M, Bubel P, Boing S, Brehler R Allergol Select. 2022; 6:167-232.

PMID: 36178453 PMC: 9513845. DOI: 10.5414/ALX02331E.

Allergen Immunotherapy: Current and Future Trends.

Pavon-Romero G, Parra-Vargas M, Ramirez-Jimenez F, Melgoza-Ruiz E, Serrano-Perez N, Teran L Cells. 2022; 11(2).

PMID: 35053328 PMC: 8774202. DOI: 10.3390/cells11020212.

EAACI Allergen Immunotherapy User's Guide.

Alvaro-Lozano M, Akdis C, Akdis M, Alviani C, Angier E, Arasi S Pediatr Allergy Immunol. 2020; 31 Suppl 25:1-101.

PMID: 32436290 PMC: 7317851. DOI: 10.1111/pai.13189.

Allergen immunotherapy phase II trials: Challenges in dose finding.

Kleine-Tebbe J, Kaul S, Mosges R Allergol Select. 2020; 3(1):1-8.

PMID: 32176223 PMC: 7066681. DOI: 10.5414/ALX02033E.

References

Dogan S, Astvatsatourov A, Deserno T, Bock F, Shah-Hosseini K, Michels A . Objectifying the conjunctival provocation test: photography-based rating and digital analysis. Int Arch Allergy Immunol. 2013; 163(1):59-68. DOI: 10.1159/000355333. View

Moingeon P . Progress in the development of specific immunotherapies for house dust mite allergies. Expert Rev Vaccines. 2014; 13(12):1463-73. DOI: 10.1586/14760584.2014.948861. View

Bergmann K, Demoly P, Worm M, Fokkens W, Carrillo T, Tabar A . Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014; 133(6):1608-14.e6. DOI: 10.1016/j.jaci.2013.11.012. View

Mosges R, Ritter B, Kayoko G, Allekotte S . Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets. Acta Dermatovenerol Alp Pannonica Adriat. 2010; 19(3):3-10. View

Compalati E, Passalacqua G, Bonini M, Canonica G . The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009; 64(11):1570-9. DOI: 10.1111/j.1398-9995.2009.02129.x. View

Klimek L, Willers J, Hammann-Haenni A, Pfaar O, Stocker H, Mueller P . Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011; 41(9):1305-12. DOI: 10.1111/j.1365-2222.2011.03783.x. View

Scalone G, Compalati E, Bruno M, Mistrello G . Effect of two doses of carbamylated allergoid extract of dust mite on nasal reactivity. Eur Ann Allergy Clin Immunol. 2014; 45(6):193-200. View

Mosges R, Pasch N, Schlierenkamper U, Lehmacher W . Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturers. Int Arch Allergy Immunol. 2006; 139(4):325-9. DOI: 10.1159/000091604. View

Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela G . Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet. 1998; 351(9103):629-32. DOI: 10.1016/S0140-6736(97)07055-4. View

10.

. ICH Harmonised Tripartite Guideline: guideline for good clinical practice. J Postgrad Med. 2002; 47(2):121-30. View

11.

Marogna M, Colombo F, Cerra C, Bruno M, Massolo A, Canonica G . The clinical efficacy of a sublingual monomeric allergoid at different maintenance doses: a randomized controlled trial. Int J Immunopathol Pharmacol. 2010; 23(3):937-45. DOI: 10.1177/039463201002300330. View

12.

Huser C, Dieterich P, Singh J, Shah-Hosseini K, Allekotte S, Lehmacher W . A 12-week DBPC dose-finding study with sublingual monomeric allergoid tablets in house dust mite-allergic patients. Allergy. 2016; 72(1):77-84. PMC: 5217067. DOI: 10.1111/all.12913. View

13.

. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 2009; 107(6):403-5. View

14.

Lombardi C, Gargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica G . Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy. 2001; 56(10):989-92. DOI: 10.1034/j.1398-9995.2001.00181.x. View

15.

Di Gioacchino M, Cavallucci E, Ballone E, Cervone M, Di Rocco P, Piunti E . Dose-dependent clinical and immunological efficacy of sublingual immunotherapy with mite monomeric allergoid. Int J Immunopathol Pharmacol. 2012; 25(3):671-9. DOI: 10.1177/039463201202500313. View

16.

Klimek L, Schendzielorz P, Pinol R, Pfaar O . Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. Clin Exp Allergy. 2012; 42(6):936-45. DOI: 10.1111/j.1365-2222.2012.03971.x. View

17.

Anantasit N, Vilaiyuk S, Kamchaisatian W, Supakornthanasarn W, Sasisakulporn C, Teawsomboonkit W . Comparison of conjunctival and nasal provocation tests in allergic rhinitis children with Dermatophagoides pteronyssinus sensitization. Asian Pac J Allergy Immunol. 2013; 31(3):227-32. DOI: 10.12932/AP0237.31.3.2013. View

18.

Mosbech H, Canonica G, Backer V, de Blay F, Klimek L, Broge L . SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015; 114(2):134-40. DOI: 10.1016/j.anai.2014.11.015. View

19.

La Grutta S, Arena A, DAnneo W, Gammeri E, Leonardi S, Trimarchi A . Evaluation of the antiinflammatory and clinical effects of sublingual immunotherapy with carbamylated allergoid in allergic asthma with or without rhinitis. A 12-month perspective randomized, controlled, trial. Eur Ann Allergy Clin Immunol. 2007; 39(2):40-4. View

20.

Calderon M, Kleine-Tebbe J, Linneberg A, de Blay F, Fernandez de Rojas D, Virchow J . House Dust Mite Respiratory Allergy: An Overview of Current Therapeutic Strategies. J Allergy Clin Immunol Pract. 2015; 3(6):843-55. DOI: 10.1016/j.jaip.2015.06.019. View